wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34297594-4676CA9A-E919-4B93-A6C9-EE2031656E48
Q34297594-4676CA9A-E919-4B93-A6C9-EE2031656E48
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34297594-4676CA9A-E919-4B93-A6C9-EE2031656E48
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
P2860
Q34297594-4676CA9A-E919-4B93-A6C9-EE2031656E48
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34297594-4676CA9A-E919-4B93-A6C9-EE2031656E48
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2dcd0dbfda526de6015c1f88a06a204f8ea3363d
P2860
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.